Momenta Pharmaceuticals, Inc. (MNTA)

[biopearl]

If I understood Wheeler correctly, there are planned releases of new products every year starting in 2020 or 2021. At least 70 patents stand between market release of biosimilar Humera. There are multiple products in development. Other than milestone payments and partnership payments, income from enox (negligible--unless there are damages from Ampha), dilution, and copox income are the drivers for the next three or four years (not including new partnerships). Does anyone see this differently? There is plenty of money in the bank at lease for the next two years. If Mylan receives approval along with Sandoz then an authorized generic from Teva looks like a given. Here we go again. Still trying to be optimistic. The autoimmune program looks very promising but with a long term horizon. Are there any other short term value creating events coming? Regards, bp